Satellos Bioscience Receives US Patent for Forazapadin
MT newswire2026/10/05 11:5807:58 AM EDT, 10/05/2026 (MT Newswires) -- Satellos Bioscience (MSLE) said Monday that it received a US patent covering the composition of matter claims for its lead clinical-stage drug candidate forazapadin to restore muscle regeneration and repair in patients with degenerative muscle diseases. The company said the patent covers a broader class of AAK1 inhibitors and related compounds under its muscle regeneration platform. Satellos said the patent provides intellectual property protection through Sept. 6, 2044. The company may also qualify for a patent term extension for forazapadin if the drug receives US marketing approval, according to Satellos. Satellos said it plans to seek inclusion of the patent in the FDA's Orange Book following potential US approval of forazapadin.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Cybertruck orders far exceed pre-production capacity, Tesla (TSLA.US) to refund deposits to a large number of customers
Elon Musk stated that Tesla will refund the Cybertruck deposits to a significant number of customers.
Barrick Gold (B.US) Q3 Results Mixed: Benefiting from Gold Price Dividend While Facing Cost Pressures
Barrick Mining (B.US) will release its financial results for the third quarter of 2026 before the U.S. stock market opens on November 9.
Europe Becomes a Safe Haven Amid AI Turbulence! Citi Turns Bullish on European Stocks, Downgrades US Stocks: Low AI Exposure Seen as Key Advantage
Citigroup strategists have downgraded the rating of U.S. stocks and upgraded the rating of European stocks, following the recent market turbulence caused by upheaval in the artificial intelligence industry.
Rumor: Tesla (TSLA.US) and SpaceX (SPCX.US) plan Terafab monthly production of one million wafers, feasibility questioned
According to reports, Tesla (TSLA.US) and SpaceX (SPCX.US) plan to achieve a production capacity of 1 million semiconductor wafers per month at the proposed Terafab factory starting in 2032.
Crypto prices
More
